The Technical Analyst
Select Language :
Kamada Ltd [KMDA]

Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic

Kamada Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals

Kamada Ltd is listed at the  Exchange

-0.27% $5.61

America/New_York / 28 mar 2024 @ 16:00


FUNDAMENTALS
MarketCap: 322.43 mill
EPS: 0.150
P/E: 37.40
Earnings Date: May 21, 2024
SharesOutstanding: 57.47 mill
Avg Daily Volume: 0.0239 mill
RATING 2024-03-28
A+
Buy
RATINGS
Rating CashFlow: Buy
Return On Equity: Neutral
Return On Asset: Strong Buy
DE: Neutral
P/E: Strong Buy
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 37.40 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
0.78x
Company: PE 37.40 | industry: PE 47.78
DISCOUNTED CASH FLOW VALUE
$7.02
(25.21%) $1.414
Date: 2024-03-29
Expected Trading Range (DAY)

$ 5.41 - 5.81

( +/- 3.53%)
ATR Model: 14 days

Forecast: 16:00 - $5.64

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $5.64
Forecast 2: 16:00 - $5.64
Forecast 3: 16:00 - $5.64
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $5.61 (-0.27% )
Volume 0.0138 mill
Avg. Vol. 0.0239 mill
% of Avg. Vol 57.82 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Kamada Ltd

Last 12 Months

Last 12 months chart data with high, low, open and close for Kamada Ltd

RSI

Last 10 Buy & Sell Signals For KMDA

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Kamada Ltd

KMDA

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Last 10 Buy Signals

Date Signal @
ARUSDMar 29 - 04:28$41.19
KCSUSDMar 29 - 04:24$11.87
FTNUSDMar 29 - 04:141.819
ORAIUSDMar 29 - 04:0814.59
IONUSDMar 29 - 04:08452.00
MXUSDMar 29 - 04:07$4.21
RETHUSDMar 29 - 04:043 905.62
ABTUSDMar 29 - 04:041.978
XU100.ISMar 29 - 04:03PTS9 101.28
DYDXUSDMar 29 - 04:003.39

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.